$BBOT News

BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,

Canaccord Genuity Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $23

BridgeBio Oncology Therapeutics Presents New Preclinical Data For BBO-11818 Inhibitor At American Association For Cancer Research Annual Meeting 2026

BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran CEO, Idan Elmelech COO, Effective April 25; Neil Kumar Appointed Executive Chairman

BridgeBio Oncology Therapeutics Reveals Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models At The AACR Annual Meeting 2026; BBO-10203 Physically And Allosterically Disrupts The Interaction Between RAS And PI3Kα, Leading To Signaling Inhibition Without Inhibiting The Kinase Activity of PI3Kα And With No Observed Hyperglycemia

BridgeBio Oncology Therapeutics shares are trading higher after the company announced that the FDA granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma.

BridgeBio Oncology Therapeutics shares are trading higher after the company announced that the FDA granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma.

FDA Grants BridgeBio Oncology Therapeutics Fast Track Designation To BBO-11818

BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter

BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028

BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

BridgeBio Announces Publication Of Preclinical Data Describing Discovery Of BBO-11818, panKRAS Inhibitor Targeting KRAS In ON And OFF States For Patients With KRAS Mutant Cancers

HC Wainwright & Co. Maintains Buy on BridgeBio Oncology, Raises Price Target to $29

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

BridgeBio Oncology Q4 EPS $(0.49) Beats $(0.56) Estimate

BridgeBio Oncology Touts “Best in RAS” Pipeline, Highlights BBO-8520 Response and Combo Tolerability

BBOT to Participate in Upcoming Investor Healthcare Conferences